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ABSTRACT: Phthalates are used as plasticizers in many of the products 
found in medical, household, and industrial applications. Much research 
has not been completed on the effects of these phthalates as potential en-
docrine disrupting chemicals (EDCs). As these chemicals are ingested, 
the mechanism by which they affect the reproductive system is largely 
unknown. The purpose of this study was to observe how 2 phthalates, Di-
n-butyl phthalate (DBP) and Diisononyl phthalate (DINP), and 2 phthal-
ate alternatives, Dioctyl terephthalate (DOTP) and BHT (butylated hy-
droxytoluene)affect uterine cells in comparison to a vehicle treatment and 
17β-Estradiol treatment. Changes in expression of mRNA were observed 
using reverse transcription polymerase chain reaction. Results from this 
study show that based on trends of change in the genes CD1, C-myc, ERα, 
PR, and HOXA10, each of the four chemical treatments changed prolifera-
tion in Ishikawa cells. Our results have opened possible classifications for 
mechanisms that the chemical treatments may follow as potential EDCs. 
INTRODUCTION. 
Endocrine disruption occurs when a synthetic chemical, endocrine disruptor, 
is absorbed into the body and disrupts the body’s normal functions by mimick-
ing or blocking hormones [1]. Endocrine disrupting chemicals lead to unnec-
essary intracellular responses by attaching to receptors and activating the cell’s 
normal response to an excessive extent or at the wrong time [2]. The disruptor 
could have an antagonistic effect by simply bonding to the cellular receptor, 
preventing the natural hormone from bonding. Disruptors can also bind to 
transport proteins which can affect metabolic rates, which affect desynthesis of 
the natural hormone [2]. Investigating EDCs is important in improving public 
health because presence of EDCs within the body can lead to reproductive dis-
eases such as endometriosis, infertility, diabetes, metabolic syndrome, breast 
or prostate cancer, early puberty, and obesity [3]. One common hormone that 
is mimicked by toxic chemicals is estrogen. Estrogen is produced in all verte-
brates and it is important that estrogen is released at the right time and stage 
in the organism to maintain homeostasis [2]. Most endocrine disruptors are 
man-made pollutants that mimic or block the function of estrogen. These com-
pounds can bind to the estrogen receptor and can cause transcription to occur, 
which may happen even when homeostasis is not disrupted [4]. Known en-
docrine disruptors such as Bisphenol-A and dichlorodiphenyltrichloroethane 
(DDT) have been extensively researched and are known to mimic estrogen in 
both male and female reproductive systems, as shown in both in vivo and in 
vitro models [5,6]. Although some phthalates are classified as endocrine dis-
rupting chemicals, many of the ones used often in industrial production have 
not been researched extensively, and therefore have not been classified as endo-
crine disrupting chemicals yet [5]. Although the phthalates Di-n-butyl phthal-
ate (DBP) and diisononyl phthalate (DINP) have been banned in production, 
phthalate alternatives such as Di-octyl terephthalate (DOTP) and butylated 
hydroxytoluene (BHT) have replaced traditional phthalates [7]. The effects of 
these chemicals on the female reproductive system have not been researched 
to a great extent. Instead of only focusing on the ability of the four potential 
endocrine disrupting chemicals (DBP, DINP, DOTP, and BHT) to interfere 
with or promote estrogenic activity, the effect of each treatment on proliferative 
genes was also observed in this study. Genes known to indicate change in pro-
liferation and differentiation include HOXA10, Cyclin D1, and C-myc, while 
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genes such as Estrogen Receptor (ER) and Progesterone Receptor (PR) were 
used to determine estrogenic properties [8,9,10,11]. We hypothesized that the 
ability of each phthalate to affect expression of each target gene will vary based 
on mechanism of action. Currently, many studies have not been completed ob-
serving the effects of phthalate and phthalate alternatives on changes of these 
target genes in Ishikawa cells or even leiomyoma or myometrium cells [5]. DBP 
has been shown to have a possibility of decreasing androgenic function, and 
therefore may act as an androgen inhibitor, but the effects on estrogen related 
genes are not clear [6]. The purpose of this study was to observe and compare 
the effects of two phthalates, DBP and DINP, and two phthalate alternatives, 
DOTP and BHT, in comparison to vehicle and 17β-estradiol (E2) treatments 
on target genes affecting proliferation and estrogenic function in Ishikawa cells. 
MATERIALS AND METHODS. 
Cell Culture and Treatment.
Ishikawa cells, a well-differentiated line of endometrial adenocarcinoma hu-
man cells which express both estrogen and progesterone receptors, were used 
because they express not only Progesterone Receptor (PR) and Estrogen 
Receptor Alpha (ERα), but also express HOXA10, Cyclin D1 (CD1), and 
C-Myc [8,11,12]. Ishikawa cells were used because they are more sensitive to 
chemical treatment than normal myometrium cells and are smaller in size, al-
lowing for culturing of more cells. However, because Ishikawa cells share the 
same hormone receptors as healthy uterine cells and tissue and both types of 
cells are found in the uterus, the results can still be applied to studies on healthy 
uterine tissue and cells [12]. The chemicals, DBP, DINP, DOTP, and BHT were 
obtained from Sigma-Aldrich Chemical Company. These chemicals were dilut-
ed in ethanol to prepare a stock solution of each chemical at 10-2 M concentra-
tion. All cells were cultured (all below passage 10) in DMEM/F121:1 (GIBCO/
BRL, Grand Island, NY) which contained 10% Fetal Bovine Serum (FBS). 
Cells were grown to confluence in two 150 mm cell culture plates and were 
maintained in a 37°C 5% CO2, humid environment within the incubator. These 
cells were trypsinized and seeded into three 6-well plates. After cells reached 
70-80% confluence, cells were starved in phenol red-free DMEM/F12 for 24 
hours. For the first experiment the starved cells were treated with DBP, DINP, 
DOTP, or BHT, at 10-5 concentration (primarily diluted to 10-2 concentration 
in ethanol and further diluted in starvation media) for 24 hours and one set of 
cells was treated with 17β-Estradiol only (E2; Sigma-Aldrich) at 10
-7 Molarity 
concentration for 24 hours. The control set of cells (VEH) was treated with the 
same starvation media which contained 10-5 concentration ethanol only. Each 
experiment was performed in triplicate. 
Reverse Transcription and Polymerase Chain Reaction (RT-PCR)
Cells were directly lysed using RLT lysis buffer and RNA was extracted using 
the RNeasy Mini Kits (QIAGEN Gmbh, Hilden, Germany). RNA was quanti-
fied and 1 μg RNA was reverse transcribed into 20 μL of complimentary DNA 
using the qScript cDNA SuperMix (Quanta BioSciences, Inc., Gaithersburg, 
MD). Using a 386-well PCR plate, 10 μL of reactant were prepared in each well. 
The reactants for each PCR reaction consisted of 3 μL of RNAse-free H2O, 5 
microliters of SYBR green DNA-binding dye (Applied Biosystems, Foster City, 
CA), 0.5 μL of reverse primer (2 micromolar), 0.5 μL of forward primer (2 
μm), and 1 μL of cDNA. The ABI Prism 7900HT Detection System (Applied 
Biosystems) was used to determine relative amounts of each transcript and 
gene expression using the setting comparative CT wherein PCR amplification 
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is parallel between all samples. Cycle Threshold (CT) is the number of cycles 
required for the fluorescent signal (after PCR reaction) to exceed the threshold 
(background reactions). CT count is inversely proportional to the amount of 
nucleic acid of the target gene in the sample. Cycling conditions started at 50° 
C for 2 min, followed by 95°C for 10 min, then 40 cycles of 95°C for 15 sec 
and 60°C for 1 min. PCR Amplification process was completed in triplicate for 
the following genes: GAPDH, Cyclin D1, C-myc, HOXA10, ER, and PR. Fold 
change was calculated by comparing CT values to those of GAPDH (unaffected 
by treatment), the housekeeping gene. The following primers were used:
GAPDH
Forward: 5’- GAAGGTGAAGGTCGGAGTC-3’
Reverse: 5’- GAAGATGGTGATGGGATTTC-3’
ERα
Forward: 5’- CACCAACCAGTGCACCATTG-3’
Reverse: 5’- AAGGTTGGCAGCTCTCATGTC-3’
C-myc
Forward: 5’-TCGGAAGGACTATCCTGCTG-3’
Reverse: 5’-GTGTGTTCGCCTCTTGACATT-3’
Cyclin D1: Ordered from Qiagen (Hs_CCND1_1_SG QuantiTect primer as-
say; Catalog Number: QT00495285)
HOXA10
Forward: 5’-AGGTGGACGCTGCGGCTAATCTCTA-3’
Reverse: 5’-GCCCCTTCCGAGAGCAGCAAAG-3’
PR
Forward: 5’-TGGAAGAAATGACTGCATCG-3’
Reverse: 5’-TAGGGCTTGGCTTTCATTTG-3’
Data Analysis Equation.
Fold Change= 2(-(Normalized CT count value for treatment-normalized CT count value for vehicle))
Equation 1: CT count value was normalized to GAPDH by subtracting coordi-
nating GAPDH value from CT count of target gene. 
Statistical Analysis.
In order to determine statistical significance of results, multivariate analysis us-
ing ANOVA statistics was performed followed by Tukey’s post - hoc test for 
significance set at two-tailed p<0.05 using kaleidagraph program (synergy 
Software, Reading, PA).
RESULTS.
The objective of completing reverse-transcription polymerase chain reaction 
was to determine change in expression of the 5 target genes marking prolifera-
tion, differentiation, and estrogen-mediated action. The housekeeping gene was 
approximately equal in Cycle threshold count for each treatment in the experi-
ment [Figure 2]. Figure 1 shows the average fold change of each gene in re-
sponse to treatment. The order of treatment shown in the graph is as follows: 
E2, VEH, DBP, DINP, DOTP, and BHT. 
HOXA10 is a transcription factor associated with uterine development. This 
gene affects cell proliferation and differentiation [8]. Differences in HOXA10 
expression may change cell proliferation [8]. All of the compounds slightly in-
creased expression of HOXA10 by approximately 20% in comparison to vehicle 
treatment [Figure 1]. The E2 treatment did not noticeably increase HOXA10 
expression [Figure 1]. Typically, HOXA10 expression in Ishikawa cells should 
be significantly upregulated by approximately 60% with the presence of E2 [8] 
however the results in our study do not support that claim. 
C-myc is a regulatory transcription factor which affects cell proliferation, cell 
growth, and differentiation. In comparison to the vehicle, all treatments in-
creased expression of C-myc. Treatment with BHT increased expression of 
C-myc by approximately 40%, while other compounds DBP, DINP, and DOTP 
increased expression of C-myc by approximately 25% [Figure 1]. Treatment 
with E2 only slightly increased expression, closer to 5% increase. 
Progesterone receptor (PR) is a major target gene of estrogen action and plays 
an important role of differentiation within the uterus. Treatment with E2 heav-
ily increased expression of PR by 32-fold compared to the Vehicle, as expected 
since Estradiol is a known PR-mediator [8]. DOTP, DBP, BHT, and DINP also 
increased expression of PR (by 50%, 40%, 25%, 20%, respectively) compared 
to the Vehicle [Figure 1]. 
Estrogen receptor is a nuclear receptor that is responsive to estrogenic com-
pounds [13]. Expression of the Estrogen Receptor in E2 treated cells was slight-
ly greater than that of the vehicle group. Compared to the Vehicle, DBP and 
DOTP slightly increased ER expression (by 10% and 20%, respectively), while 
DINP and BHT treatments decreased the expression of ER (by 10% and 20%, 
respectively). Expression of CD1 was approximately the same in both Vehicle 
treated cells and E2 treated cells. 
Cyclin D1 (CD1) works primarily during the G1 phase of the cell cycle and is 
shown to be a marker of cell proliferation [10]. There was an increase in expres-
sion of CD1 in cells treated with DBP, DINP, and DOTP (by 25%, 5%, and 15%, 
respectively) while cells treated with BHT showed a decrease in expression of 
CD1 by approximately 25% compared with the Vehicle group [Figure 1].
Figure 1. Fold changes calculated using Equation1 are shown for each target gene. 
The most statistically significant difference in comparison to vehicle occurred in 
CD1 expression when cells are treated with BHT (p=0.09); DBP and BHT showed 
the most statistically significant differences, compared to each other particularly in 
expression of CD1 and Cym-C (p=0.09,0.08, respectively). Treatment with BHT 
significantly decreased CD1 expression. Phthalate and Phthalate alternatives: DBP, 
di-n-butyl phthalate; DINP, diisononyl phthalate; DOTP, dioctylterephthalate; 
BHT, butylated hydroxytoluene; E2, 17β-Estradiol; Veh, Control. 
Figure 2. Cycle counts were calculated to average fold change using Equation 1. 
A standard deviation below 1 was observed for each group. Based on these results 
from the Comparative CT analysis, fold magnification or decrease was calculated 
using equation 1. The normalizing gene (GAPDH) did not vary much between 
treatments (p>0.4). 
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Overall, although there was not much statistically significant change [p>0.1], 
trends observed may provide insight into the potential pathways and mecha-
nisms of action of the four target chemicals. In a similar primarily quantitative 
PCR based study, although only around 1.5-2 fold change in many of the genes 
was seen by treating the cells with compound, when cells were treated with 
compound and estradiol together, magnified change was seen in the same trend 
[8]. Therefore, the trends noticed in this study are still valuable in investigating 
mechanisms of these chemicals.
DISCUSSION.
Previously, many studies have not been conducted observing the effects of 
DBP, DINP, DOTP, and BHT on expression of HOXA10, C-myc, CD1, PR, 
and ERα. However, based on previous studies, it is known that Estradiol (E2) 
is a major regulator of growth and differentiation within endometrial cells and 
increases expression of PR and ER [13]. We hypothesized that the ability of 
each phthalate or phthalate alternative to affect expression of each target gene 
will vary. Specifically, based on studies conducted on the male reproductive sys-
tem, DBP may act as an estrogenic compound and therefore it is hypothesized 
that DBP may also increase proliferation, since within the female reproductive 
system proliferation is increased in the presence of estrogenic compounds [6]. 
Although estrogenic compounds are known to increase proliferation within 
endometrial cells, increase in proliferation does not necessarily indicate pres-
ence of an estrogenic compound. However, these compounds may be classified 
as potential endocrine disruptors which are characterized as substances that 
have properties that may lead to endocrine disruption [3]. In this study, for 
all compounds, except for BHT, as c-myc is upregulated, CD1 is also upregu-
lated, which is expected because as C-myc is increased in expression, the ex-
pression of cyclins is also upregulated. Since both genes are upregulated, these 
compounds likely contribute to increase in cell proliferation, since these genes 
control cell growth and proliferation. 
PR and ERα are activated by estrogenic action [13]. In DBP and DOTP the 
correlation between increase in expression of both PR and ER indicate that 
these compounds may contribute to estrogenic activity, and may be potential 
endocrine disruptors. However, in DINP and BHT, while expression of PR was 
increased, expression of ER was decreased in comparison to the vehicle group. 
In a previous study, it was shown that progesterone downregulated nuclear es-
trogen receptor while upregulating cytosol progesterone receptor [13]. Based 
on the similar behavior that DINP and BHT exhibit, DINP and BHT may fol-
low a mechanism similar to progesterone. However, both of these observations 
must be verified through further future experimentation. As shown in other 
studies, treating cells with just the target compound will lead to a less promi-
nent change in expression of target genes [8]. However, in combination with 
E2, these treatments show magnified results of the changes already seen. 
Although this study showed results for the endocrine disruptive effects of DBP, 
DINP, DOTP, and BHT only on Ishikawa cells, the claims and observations 
reported can be applied to healthy myometrium cells and even leiomyoma 
cells. Before deciding to test only Ishikawa cells, the effects of these chemicals 
on normal myometrium cells and leiomyoma cells was observed, and slightly 
similar trends were observed, however it was difficult to confirm positive cor-
relation since these cells did not respond as strongly to the treatment, partly 
because of the larger cell size and experimental limitations such as less mRNA 
collection and number of cells cultured. 
In addition, although the changes in this study may seem subtle, we argue that in 
combination with other natural hormones in an in vivo environment, the actual 
effect of phthalate or phthalate alternative exposure is likely to be more impact-
ful [8]. Based on similar studies, it is observed that fold change increases with 
the addition of natural hormones such as estradiol in addition to the chemical.
It is important to remember that our results do not declare DBP, DINP, DOTP, 
and BHT as endocrine disruptors, but as potential endocrine disruptors because 
we must perform other quantitative procedures in order secure knowledge of 
these chemical mechanisms. However, our study found that the treatment groups 
changed proliferation of Ishikawa cells. Also, we think that DBP and DOTP may 
follow mechanisms similar to estradiol while DINP and BHT may follow mecha-
nisms more similar to progesterone, however this hypothesis can only be validat-
ed with further experimentation. Therefore, it is important to control the use of 
these substances in industrial, medicinal, and household products because of the 
effects of these chemicals on the female reproductive system. 
FUTURE DIRECTIONS/CONCLUSIONS.
In order to better understand the further effects of cell proliferation that sev-
eral of these compounds induce, future investigations will consist of testing 
for change in expression of genes associated with oncogenesis and apoptosis. 
In addition, protein analysis will be completed in order to observe changes in 
trend with the results observed in this study due to change in transcription and 
translation. Previously, we employed similar testing using myometrium and 
leiomyoma cells, however tests repeated in Ishikawa cells produced magnified 
results, likely because of the smaller cell size (allows collection of more RNA) 
and the sensitive nature of these cells. It would also be advantageous to com-
plete similar experimentation within an in vivo environment or with longer 
chemical exposure. In addition, in order to further observe mechanisms of ac-
tion of these chemicals and verify the previously discussed hypotheses based 
on observations in the current study, these chemicals will be compared in ef-
fect to Progesterone and estradiol using gene targets such as KLF11 and SGK1 
along with others. 
In conclusion the results of this study have opened up options to categorize the 
mechanisms of four popularly used phthalates/phthalate alternatives. In addi-
tion, it is has also shown that observing changes in expression of PR and ER 
with chemical treatment and documenting these trends in comparison to natu-
ral hormones may help us better understand the potential effects and diseases 
that these chemicals can cause when ingested in excess. 
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